The clinical study of using DLI+IL-2 after Mixed-HSCT in acute myelogenous leukemia
- VernacularTitle:DLI+IL-2后续治疗混合造血干细胞移植后的急性髓性白血病
- Author:
Cunbang WANG
;
Hai BAI
;
Yingxian OU
;
Yaozhu PAN
;
Qian ZHANG
;
Rui XI
;
Xiaojing WANG
- Publication Type:Journal Article
- Keywords:
Mixed-HSCT;
DLI;
IL-2;
Acute myelogenous leukemia
- From:
Chinese Journal of Postgraduates of Medicine
2006;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To approach curative effect of using DLI +IL-2 as immunobiotherapy after Mixed-HSCT in acute myelogenous leukemia.MethodAfter times of chemotherapy,8 cases of patients with acute myelogenous leukemia received Mixed-HSCT,then were treated with DLI +IL-2 for 2-7 times.Observed clinical effect for 1 to 5 years.Result DFS in 8 cases of patients with acute myelogenous leukemia received Mixed-HSCT and treated with DLI +IL-2 for 2-7 times were 62.5%.There were no GVHD.Conclusion Immuno-biotherapy with DLI +IL-2 after Mixed-HSCT in patients of acute myelogenous leukemia may be a method to increase DFS efficiently.
